The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Molecular imaging of gliomas with PET: Opportunities and limitations
Open accessAbstract
Neuroimaging enables the noninvasive evaluation of glioma and is considered to be one of the key factors for individualized therapy and patient management, since accurate diagnosis and demarcation of viable tumor tissue is required for treatment planning as well as assessment of treatment response. Conventional imaging techniques like MRI and CT reveal morphological information but are of limited value for the assessment of more specific and reproducible information about biology and activity of the tumor. Molecular imaging with PET is increasingly implemented in neuro-oncology, since it provides additional metabolic information of the tumor, both for patient management as well as for evaluation of newly developed therapeutics. Different molecular processes have been proposed to be useful, like glucose consumption, expression of amino acid transporters, proliferation rate, membrane biosynthesis, and hypoxia. Thus, PET might help neuro-oncologists gain further insights into tumor biology by "true molecular imaging" as well as understand treatment-related phenomena. This review describes the method of PET acquisition as well as the tracers used to image biological processes in gliomas. Furthermore, it considers the clinical impact of PET on the use of currently available radiotracers, which were shown to be potentially valuable for discrimination between neoplastic and nonneoplastic tissue, as well as on tumor grading, determinination of treatment response, and providing an outlook toward further developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“Several efforts in this area of research are leading to the development of antiangiogenic molecules for cancer treatment.(44) The ability to measure blood flow noninvasively may be of importance in monitoring glioma therapies.”
BackgroundWen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
American Journal of Neuroradiology
(2020) · American Journal of Neuroradiology · doi:10.3174/ajnr · Cited by 2,453
Molecular imaging of cancer with positron emission tomography
Gambhir, S. S. (2002) · Nature Reviews Cancer · doi:10.1038/nrc882 · Cited by 1,656
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H.-J., Stayanoff, J. C., Lawhorn-Crews, J. M., Obradovich, J. E., Muzik, O., & Mangner, T. J. (1998) · Nature Medicine · doi:10.1038/3337 · Cited by 1,204
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Law, M., Yang, S., Wang, H., Babb, J. S., Johnson, G., Cha, S., Knopp, E. A., & Zagzag, D. (2003) · PubMed Central · Cited by 1,084
Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality
Ling, C. C., Humm, J., Larson, S., Amols, H., Fuks, Z., Leibel, S., & Koutcher, J. A. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00467-3 · Cited by 926
Di Chiro, G., DeLaPaz, R. L., Brooks, R. A., Sokoloff, L., Kornblith, P. L., Smith, B. H., Patronas, N. J., Kufta, C. V., Kessler, R. M., Johnston, G. S., et al. (1982) · Neurology · doi:10.1212/wnl.32.12.1323 · Cited by 752
Kumar, A. J., Leeds, N. E., Fuller, G. N., Van Tassel, P., Maor, M. H., Sawaya, R. E., & Levin, V. A. (2000) · Radiology · doi:10.1148/radiology.217.2.r00nv36377 · Cited by 669
Pauleit, D. (2005) · Brain · doi:10.1093/brain/awh399 · Cited by 634
Tumour phospholipid metabolism
Podo, F. (1999) · NMR in Biomedicine · doi:10.1002/(sici)1099-1492(199911)12:7<413::aid-nbm587>3.0.co;2-u · Cited by 579
Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging.
Wester, H. J., Herz, M., Weber, W., et al. (1999) · PubMed · Cited by 466
Clinical Applications of PET in Brain Tumors
Chen, W. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037689 · Cited by 449
Chiro, G. D. (1987) · Investigative Radiology · doi:10.1097/00004424-198705000-00002 · Cited by 442
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen, W., Cloughesy, T. F., Kamdar, N. V., Satyamurthy, N., Bergsneider, M., Liau, L. M., Mischel, P. S., Czernin, J., Phelps, M. E., & Silverman, D. H. S. (2005) · PubMed · Cited by 437
DIETARY CHOLINE: BIOCHEMISTRY, PHYSIOLOGY, AND PHARMACOLOGY
Zeisel, S. H. (1981) · Annual Review of Nutrition · doi:10.1146/annurev.nu.01.070181.000523 · Cited by 435
Terakawa, Y., Tsuyuguchi, N., Iwai, Y., Yamanaka, K., Higashiyama, S., Takami, T., & Ohata, K. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048082 · Cited by 419
Limitations of stereotactic biopsy in the initial management of gliomas
Jackson, R. J., Fuller, G. N., Abi-Said, D., Lang, F. F., Gokaslan, Z. L., Shi, W. M., Wildrick, D. M., & Sawaya, R. (2001) · Neuro-Oncology · doi:10.1093/neuonc/3.3.193 · Cited by 416
Chen, W., Silverman, D. H. S., Delaloye, S., Czernin, J. G., Kamdar, N. V., Pope, W. B., Satyamurthy, N., Schiepers, C. W., & Cloughesy, T. F. (2006) · PubMed · Cited by 407
Prediction of survival in glioma patients by means of positron emission tomography
Patronas, N. J., Chiro, G. D., Kufta, C., Bairamian, D., Kornblith, P. L., Simon, R., & Larson, S. M. (1985) · Journal of Neurosurgery · doi:10.3171/jns.1985.62.6.0816 · Cited by 405
Chen, W., Delaloye, S., Silverman, D. H. S., Geist, C., Czernin, J., Sayre, J., Satyamurthy, N., Pope, W., Lai, A., Phelps, M. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5825 · Cited by 393
Positron emission tomography in patients with glioma a predictor of prognosis
Alavi, J. Β., Alavi, A., Chawluk, J. B., Kushner, M., Powe, J., Hickey, W. F., & Reivich, M. (1988) · Cancer · Cited by 373
Grosu, A. L., Weber, W. A., Franz, M., Stärk, S., Piert, M., Thamm, R., Gumprecht, H., Schwaiger, M., Molls, M., & Nieder, C. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.01.056 · Cited by 373
How often are nonenhancing supratentorial gliomas malignant? A population study
Scott, J. N., Brasher, P. M. A., Sevick, R. J., Rewcastle, N. B., & Forsyth, P. A. (2002) · Neurology · doi:10.1212/wnl.59.6.947 · Cited by 366
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. C. Y., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. E., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 357
Kaschten, B., Stevenaert, A., Sadzot, B., Deprez, M., Degueldre, C., Fiore, G. D., Luxen, A., & Reznik, M. (1998) · PubMed · Cited by 327
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Box, P. (2005) · Dkgest of the World Latest Medical Information · Cited by 299
Prodrug strategies in cancer therapy
Denny, W. A. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01253-3 · Cited by 290
Pöpperl, G., Kreth, F. W., Mehrkens, J. H., Herms, J., Seelos, K., Koch, W., Gildehaus, F. J., Kretzschmar, H. A., Tonn, J. C., & Tatsch, K. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0534-y · Cited by 288
Self-citationPrediction of Pathology and Survival by FDG PET in Gliomas
Padma, M. V., Said, S., Jacobs, M., Hwang, D. R., Dunigan, K., Satter, M., Christian, B., Ruppert, J., Bernstein, T., Kraus, G., et al. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1025665820001 · Cited by 277
Journal of Computer Assisted Tomography
&NA; (1991) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199111000-00044 · Cited by 273
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P., & Cloughesy, T. F. (2006) · Neurology · doi:10.1212/01.wnl.0000208958.29600.87 · Cited by 271
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Chamberlain, M. C. (2006) · Neurology · doi:10.1212/01.wnl.0000250628.10420.d8 · Cited by 264
Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3652 · Cited by 261
Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.
Pirotte, B. J. M., Goldman, S., Massager, N., David, P., Wikler, D., Vandesteene, A., Salmon, I. J., Brotchi, J., & Levivier, M. (2004) · PubMed · Cited by 248
Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas
Kunz, M., Thon, N., Eigenbrod, S., Hartmann, C., Egensperger, R., Herms, J., Geisler, J., la Fougere, C., Lutz, J., Linn, J., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq196 · Cited by 246
Self-citationJacobs, A. H., Thomas, A., Kracht, L., Li, H., Dittmar, C., Garlip, G., Galldiks, N., Klein, J. C., Sobesky, J., Hilker, R., et al. (2005) · PubMed · Cited by 245
Grosu, A., Weber, W., Riedel, E., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.01.045 · Cited by 242
Claus, E. B., & Black, P. M. (2006) · Cancer · doi:10.1002/cncr.21733 · Cited by 226
Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole.
Valk, P. E., Mathis, C. A., Prados, M. D., Gilbert, J. C., & Budinger, T. F. (1992) · PubMed · Cited by 224
Bruehlmeier, M., Roelcke, U., Schubiger, P. A., & Ametamey, S. M. (2004) · PubMed · Cited by 214
Van Laere, K., Ceyssens, S., Van Calenbergh, F., de Groot, T., Menten, J., Flamen, P., Bormans, G., & Mortelmans, L. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1564-3 · Cited by 212
PET in differentiation of recurrent brain tumor from radiation injury.
Langleben, D. D., & Segall, G. M. (2000) · PubMed · Cited by 210
In vivo imaging of oligonucleotides with positron emission tomography
Tavitian, B., Terrazzino, S., Kühnast, B., Marzabal, S., Stettler, O., Dollé, F., Deverre, J.-R., Jobert, A., Hinnen, F., Bendriem, B., et al. (1998) · Nature Medicine · doi:10.1038/nm0498-467 · Cited by 200
Schnell, O., Krebs, B., Carlsen, J., Miederer, I., Goetz, C., Goldbrunner, R. H., Wester, H.-J., Haubner, R., Pöpperl, G., Holtmannspötter, M., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-024 · Cited by 199
Self-citationKato, T., Shinoda, J., Nakayama, N., et al. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1008 · Cited by 199
Positron Emission Tomography for Radiation Treatment Planning
Grosu, A., Piert, M., Weber, W., Jeremic, B. M., Picchio, M., Schratzenstaller, U., Zimmermann, F. B., Schwaiger, M., & Molls, M. (2005) · Strahlentherapie und Onkologie · doi:10.1007/s00066-005-1422-7 · Cited by 197
Sugar and Amino Acid Transport by Cells in Culture — Differences between Normal and Malignant Cells
Deykin, D., Balko, C., & Isselbacher, K. J. (1972) · New England Journal of Medicine · doi:10.1056/nejm197204272861707 · Cited by 190
Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors
Barker, F. G., Chang, S. M., Huhn, S. L., Davis, R. L., Gutin, P. H., McDermott, M. W., Wilson, C. B., & Prados, M. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970901)80:5<936::aid-cncr15>3.0.co;2-x · Cited by 187
Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma
Floeth, F. W., Pauleit, D., Sabel, M., Stoffels, G., Reifenberger, G., Riemenschneider, M. J., Jansen, P., Coenen, H. H., Steiger, H.-J., & Langen, K.-J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037895 · Cited by 186
Ishiwata, K., Kubota, K., Murakami, M., et al. (1993) · PubMed · Cited by 186
Spence, A. M., Muzi, M., Mankoff, D. A., O’Sullivan, S., Link, J. M., Lewellen, T. K., Lewellen, B., Pham, P., Minoshima, S., Swanson, K. R., et al. (2004) · PubMed · Cited by 182
Molecular diagnostics of gliomas: the clinical perspective
Tabatabai, G., Stupp, R., van den Bent, M. J., Hegi, M. E., Tonn, J. C., Wick, W., & Weller, M. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0750-6 · Cited by 178
Self-citationSchnell, O., Krebs, B., Wagner, E., Romagna, A., Beer, A. J., Grau, S. J., Thon, N., Goetz, C., Kretzschmar, H. A., Tonn, J., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00137.x · Cited by 177
Self-citationCher, L., Murone, C., Lawrentschuk, N., Ramdave, S., Papenfuss, A. T., Hannah, A., O'Keefe, G. J., Sachinidis, J. I., Berlangieri, S. U., Fabinyi, G., et al. (2006) · PubMed · Cited by 175
Jacobs, A. H., Kracht, L. W., Gossmann, A., Rüger, M. A., Thomas, A. V., Thiel, A., & Herholz, K. (2005) · NeuroRX · doi:10.1602/neurorx.2.2.333 · Cited by 173
Expression of Integrin ανβ3 in Small Blood Vessels of Glioblastoma Tumors
Gladson, C. L. (1996) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199611000-00005 · Cited by 162
Pirotte, B. J. M., Levivier, M., Goldman, S., Massager, N., Wikler, D., Dewitte, O., Bruneau, M., Rorive, S., David, P., & Brotchi, J. (2009) · Neurosurgery · doi:10.1227/01.neu.0000338949.94496.85 · Cited by 161
Kong, X., Zhu, Q. Y., Vidal, P. M., Watanabe, K. A., Polsky, B., Armstrong, D., Ostrander, M., Lang, S. A., Muchmore, E., & Chou, T. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.4.808 · Cited by 159
Fueger, B. J., Czernin, J., Cloughesy, T., Silverman, D. H., Geist, C. L., Walter, M. A., Schiepers, C., Nghiemphu, P., Lai, A., Phelps, M. E., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.078592 · Cited by 159
De Witte, O., Levivier, M., Violon, P., Salmon, I., Damhaut, P., Wikler, D., Hildebrand, J., Brotchi, J., & Goldman, S. (1996) · Neurosurgery · doi:10.1097/00006123-199609000-00007 · Cited by 158
New advances that enable identification of glioblastoma recurrence
Yang, I., & Aghi, M. K. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.150 · Cited by 153
Lee, I. H., Piert, M., Gomez‐Hassan, D. M., Junck, L., Rogers, L. R., Hayman, J. A., Haken, R. K. T., Lawrence, T. S., Cao, Y., & Tsien, C. I. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.04.050 · Cited by 150
Correlation of glucose consumption and tumor cell density in astrocytomas
Herholz, K., Pietrzyk, U., Voges, J., Schröder, R., Halber, M., Treuer, H., Sturm, V., & Heiss, W. (1993) · Journal of neurosurgery · doi:10.3171/jns.1993.79.6.0853 · Cited by 144
Swanson, K. R., Chakraborty, G., Wang, C. H., Rockne, R. C., Harpold, H. L. P., Muzi, M., Adamsen, T. C. H., Krohn, K. A., & Spence, A. M. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.055467 · Cited by 143
Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin
Mahmood, A., Lu, D., Qu, C., Goussev, A. V., Zhang, Z. G., Lu, C., & Chopp, M. (2007) · Journal of neurosurgery · doi:10.3171/jns-07/08/0392 · Cited by 138
Positron emission tomography imaging of regional cerebral glucose metabolism
Alavi, A. A., Dann, R., Chawluk, J. B., Alavi, J. Β., Kushner, M., & Reivich, M. (1986) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(86)80002-2 · Cited by 134
Goldman, S., Levivier, M., Pirotte, B. J. M., Brucher, J.-M., Wikler, D., Damhaut, P., Stanus, E., Brotchi, J., & Hildebrand, J. G. (1996) · Cancer · Cited by 132
[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
Weber, D. C., Zilli, T., Buchegger, F., Casanova, N., Haller, G., Rouzaud, M., Nouet, P., Dipasquale, G., Ratib, O. M., Zaidi, H., et al. (2008) · Radiation Oncology · doi:10.1186/1748-717x-3-44 · Cited by 118
Quantitative imaging biomarkers in neuro-oncology
Waldman, A. D., Jackson, A., Price, S. J., Clark, C. A., Booth, T. C., Auer, D. P., Tofts, P. S., Collins, D. J., Leach, M. O., & Rees, J. H. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.92 · Cited by 108
Methyl-l-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma
Ullrich, R. T., Kracht, L., Brunn, A., Herholz, K., Frommolt, P., Miletić, H., Deckert, M., Heiss, W., & Jacobs, A. H. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.065904 · Cited by 94
Glioma surgery using a multimodal navigation system with integrated metabolic images
Tanaka, Y., Nariai, T., Momose, T., et al. (2008) · Journal of neurosurgery · doi:10.3171/2008.4.17569 · Cited by 93
Moulin-Romsee, G., D’Hondt, E., de Groot, T., et al. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0557-4 · Cited by 91
Solitary Brain Lesions Enhancing at MR Imaging: Evaluation with Fluorine 18–Fluorocholine PET
Kwee, S. A., Ko, J. P., Jiang, C. S., et al. (2007) · Radiology · doi:10.1148/radiol.2442060898 · Cited by 91
Expression of Facilitative Glucose Transporter Isoforms in Human Brain Tumors
Nagamatsu, S., Sawa, H., Wakizaka, A., & Hoshino, T. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb07441.x · Cited by 91
Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.
Weber, W., Bartenstein, P., Groß, M. W., Kinzel, D., Daschner, H., Feldmann, H. J., Reidel, G., Ziegler, S. I., Lumenta, C. B., Molls, M., et al. (1997) · PubMed · Cited by 89
Self-citationRinglike uptake of [18F]FDG in brain abscess: a PET study.
Sasaki, M., Ichiya, Y., Kuwabara, Y., Otsuka, M., Tahara, T., Fukumura, T., Gunasekera, R. D., & Masuda, K. (1990) · PubMed · Cited by 86
Stockhammer, F., Misch, M., Horn, P., Koch, A., Nyuyki, F., & Plotkin, M. (2009) · Acta Neurochirurgica · doi:10.1007/s00701-009-0462-7 · Cited by 70
Tsuyuguchi, N., Sunada, I., Ohata, K., Takami, T., Nishio, A., Hara, M., Kawabe, J., Okamura, T., & Ochi, H. (2003) · Annals of Nuclear Medicine · doi:10.1007/bf02988258 · Cited by 61
Torii, K., Shiomi, S., Kawabe, J., Tsuyuguchi, N., Sunada, I., & Hara, M. (2005) · Annals of Nuclear Medicine · doi:10.1007/bf02985116 · Cited by 59
Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours
Huang, Z., Zuo, C., Guan, Y., Zhang, Z., Liu, P., Xue, F., & Lin, X. (2008) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3282f4a21e · Cited by 43
Potential Applications of PET Imaging in Developing Novel Cancer Therapies
Hustinx, R., Eck, S. L., & Alavi, A. A. (2000) · Journal of Vascular and Interventional Radiology · doi:10.1016/s1051-0443(00)70185-0 · Cited by 18
Cited by
Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Albert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C., Pope, W., Law, I., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 744
Self-citationCGCG clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Mao, Y., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 607
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802997-8.00023-2 · Cited by 472
Metadata
- Authors
- la Fougere, C., Suchorska, B., Bartenstein, P., Kreth, F.-W., & Tonn, J.-C.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07-13
- Volume
- 13
- Issue
- 8
- Pages
- 806-819
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2128225881
- Cited by
- 274
- References
- 84
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.